Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2024 16:01 ET | Source: Nkarta, Inc.

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies today...
May 09, 2024 16:01 ET | Source: Nkarta, Inc.

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash...
April 03, 2024 16:02 ET | Source: Nkarta, Inc.

Nkarta to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
March 25, 2024 06:30 ET | Source: Nkarta, Inc.

Nkarta Announces Pricing of $240 Million Underwritten Offering

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the...
March 21, 2024 16:01 ET | Source: Nkarta, Inc.

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletionAdditional B-cell mediated autoimmune diseases under...
February 28, 2024 08:01 ET | Source: Nkarta, Inc.

Nkarta to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
December 09, 2023 20:31 ET | Source: Nkarta, Inc.

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...
November 09, 2023 16:02 ET | Source: Nkarta, Inc.

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

FDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune diseaseNKX019, a first-in-class engineered NK cell therapy, has disease-modifying potential in autoimmune disease...
November 07, 2023 08:02 ET | Source: Nkarta, Inc.

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...
October 17, 2023 07:01 ET | Source: Nkarta, Inc.

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell...